Overview

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
0
Participant gender:
Female
Summary
Epithelial ovarian cancer is mostly diagnosed at late stage (III/IV), and the standard treatment for ovarian cancer includes primary debulking surgery and platinum-based adjuvant chemotherapy. However, scholars suggest that neoadjuvant chemotherapy can be used to reduce the tumor load and control the patient's condition. The aim of this study is to verify the efficacy of primary debulking surgery versus neoadjuvant chemotherapy.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fudan University
Treatments:
Carboplatin
Paclitaxel
Criteria
Inclusion Criteria:

- Female patients over 18 years of age.

- ECOG 0-2

- Clinically confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal
cancer

- FIGO2014 stage III/IV

- Sign the informed consent form

- Good compliance and agree to cooperate with survival follow-up

Exclusion Criteria:

- Patients with large abdominal masses or other reasons for not being able to tolerate
surgical treatment

- Patients with severe medical comorbidities that cannot be corrected in the short term
and are not suitable for tumor cytoreductive surgery

- Patients with contraindications to chemotherapy

- Patients with a history of psychotropic substance abuse and unable to quit or patients
with mental disorders

- Patients with serious safety hazards or concomitant diseases that, in the judgment of
the institution, would affect the patient's ability to complete the study